Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Drug Profile

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Alternative Names: BK 1301; DTaP vaccine - BIKEN/Mitsubishi Tanabe Pharma; Tribik

Latest Information Update: 22 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 30 Apr 2015 Mitsubishi Tanabe Pharma files sNDA for stage 2 vaccination in prophylaxis of patients with Diphtheria, Pertusis and Tetanus in Japan (Mitsubishi Tanabe Pharma pipeline, May 2015)
  • 01 Aug 2014 Mitsubishi Tanabe Pharma completes a phase III trial in Diphtheria, Pertussis and Tetanus (Prevention, In adolescents) in Japan (NCT02118961)
  • 30 Apr 2014 Mitsubishi Tanabe Pharma in collaboration with the Research Foundation for Microbial Diseases of Osaka University initiates phase-III clinical trials in Pertussis (Prevention, In adolescents) in Japan (SC) (NCT02118961)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top